The pharmaceutical giant has been neck-and-neck with its competitor, Novo Nordisk — maker of Ozempic — to do so, according to previous reports from The Wall Street Journal. Both Mounjaro and Ozempic are FDA-approved drug treatments for diabetes, but after seeing benefits related to weight loss, some physicians have begun to prescribe them toward that end. The phase three clinical trial Eli Lilly has entered into will evaluate Mounjaro’s efficacy in this vein and allow it to ultimately be approved for obesity, if results trend well.
Mounjaro has been found to reduce weight for patients with obesity by up to 22.7 percent while its competitor, Ozempic was found to cut weight by just 17 percent.
The clinical trial will involve 700 adults who have a body mass index that falls into the range for obesity and have also been previously diagnosed with hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. Participants must also have a history of at least one previously unsuccessful attempt to lose weight with dietary means.
The study will measure a percent change in baseline body weight reduction over the course of 72 weeks.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
